A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity

被引：0
|
作者：
Ding, Ke
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-768-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
768-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of bexicaserin in adolescent and adult patients with developmental and epileptic encephalopathies: Results of the phase 1b/2a PACIFIC study
    Kaye, R.
    Orevillo, C.
    Dlugos, D. J.
    Scheffer, I. E.
    EPILEPSIA, 2024, 65 : 30 - 30
  • [42] Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis
    Aronne, L.
    Harris, M. S.
    Roberts, M. S.
    Suschak, J.
    Tomah, S.
    He, L.
    Yang, J.
    Frias, J. P.
    Browne, S. K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S33 - S34
  • [43] Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, doubleblind, placebo-controlled, phase 1b/2a trial
    Mazighi, Mikael
    Koehrmann, Martin
    Lemmens, Robin
    Lyrer, Philippe A.
    Molina, Carlos A.
    Richard, Sebastien
    Toni, Danilo
    Pletan, Yannick
    Sari, Anouar
    Meilhoc, Adeline
    Jandrot-Perrus, Martine
    Binay, Sophie
    Avenard, Gilles
    Comenducci, Andrea
    Grouin, Jean-Marie
    Grotta, James C.
    LANCET NEUROLOGY, 2024, 23 (02): : 157 - 167
  • [44] The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study
    Fan, Yuxin
    Yuan, Jiandong
    Dong, Lichun
    Yu, Chongjing
    Ding, Haifeng
    Xie, Daosheng
    Guan, Runfang
    Li, Ruixia
    Zou, Wenhong
    Long, Shuxian
    Chen, Jion
    Huang, Yu
    Yang, Mei
    He, Jianchang
    Wen, Weibo
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2110 - 2119
  • [45] SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND EFFICACY OF ARGX-119 IN PARTICIPANTS WITH DOK7-CONGENITAL MYASTHENIC SYNDROMES: PHASE 1B STUDY IN PROGRESS
    Lochmuller, Hanns
    Burden, Steven J.
    Avendano, Javier
    Van Bragt, Tonke
    Gelinas, Deborah
    Dincq, Stephanie
    Sumbul, Anne
    Vanhauwaert, Roeland
    Shilling, Rebecca
    Palace, Jacqueline
    MUSCLE & NERVE, 2024, 70 (03) : 530 - 530
  • [46] SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL GLP-1/FGF21 DUAL AGONIST HEC88473 IN TYPE 2 DIABETES PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1b/2a MULTIPLE-ASCENDING-DOSE STUDY
    Xiang, Lin
    Ding, Hua Yan
    Yan, Jiangyu
    Luo, Lin
    Zhang, Hong
    Xie, Can
    Peng, Yu Yu
    Chen, Hong
    Li, Qian Qian
    Li, Xiao Ping
    Zhuang, Yu Lei
    Guo, Linfeng
    HEPATOLOGY, 2024, 79 (02) : E67 - E68
  • [47] Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
    Enebo, Lone B.
    Berthelsen, Kasper K.
    Kankam, Martin
    Lund, Michael T.
    Rubino, Domenica M.
    Satylganova, Altynai
    Lau, David C. W.
    LANCET, 2021, 397 (10286): : 1736 - 1748
  • [48] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    LANCET, 2021, 398 (10295): : 143 - 155
  • [49] A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Participants with Type 2 Diabetes Mellitus (T2DM)
    Coll, Blai
    Zhang, Jinqiang
    Chen, Libo
    Ibarra, Lani
    Yue, Huibin
    Barth, Aline
    Bach, Mark A.
    DIABETES, 2024, 73
  • [50] Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia
    Lin, Tara L.
    Wood, Robyn
    Ham, Tammy
    Sullivan, Taegen
    Dandawate, Prasad
    Anant, Shrikant
    Santaguida, Marianne T.
    Toren, Paul
    Jensen, Roy A.
    Taylor, John A.
    Baltezor, Michael Jay
    Dalton, Michael
    Meyer, Fred
    McBride, John
    Umbreit, Jay Nicholas
    McCulloch, William
    Vanderlaag, Kathryn
    Wagner, Joseph
    Weir, Scott James
    Smith, B. Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345